ACIU (AC Immune) Valuation Rank


ACIU AC Immune SA ACIU
26 GF Score
Price $2.66
GF Value $0.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AC Immune Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

AC Immune Valuation Rank Related Terms

ACIU
26GF Score
AC Immune SA ACIU
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AC Immune (ACIU) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be overvalued. The current stock price of $2.66 is trading 254.7% above its estimated GF Value™ of $0.75. GuruFocus considers AC Immune to be Significantly Overvalued.

Key valuation signals for ACIU:

  • Valuation Rank:
  • GF Value™: $0.75 vs. price of $2.66 (254.7% above fair value)
  • GF Score™: 26/100 with 6 warning signs

No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AC Immune Business Description

Other Exchanges IMR:Germany
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
26GF Score

Get the complete analysis for ACIU

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.66
Price
$0.75
GF Value